TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00704821
Drug: PTC299
Normalized name: PTC299
DrugBank: PTC299 (DB05173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT00704821
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT00108394
Drug: pamidronate
Normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00006451
Drug: anti-thymocyte globulin
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006451
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006451
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04898270
Drug: Flupentixol
Normalized name: Flupentixol
DrugBank: Flupentixol (DB00875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupentixol tablets are indicated for:~• maintenance therapy of chronic schizophrenic patients whose main manifestations do not include excitement, agitation, or hyperactivity.
Study: NCT04898270
Drug: Multi-acting receptor-targeted antipsychotics (MARTAs)
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-acting receptor-targeted antipsychotics (MARTAs)
Study: NCT02690857
Drug: Docosahexaenoic acid
Normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02690857
Drug: Sunflower Oil
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00496730
Drug: Comparator: atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atorvastatin 10 mg; tablet, once daily, 8 Weeks
Study: NCT03633175
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg vaginal progesterone \[Prontogest® vaginal pessaries 400, Marcyrl, Cairo, Egypt\] will be given, once at bed time starting from 26-28 weeks of gestation till 36 weeks of gestation or delivery (which is closer).
Study: NCT04542759
Drug: Besifloxacin Ophthalmic
Normalized name: besifloxacin ophthalmic
DrugBank: Besifloxacin (DB06771)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylaxis for endophthalmitis
Study: NCT04542759
Drug: Hydroxypropyl Methylcellulose Ophthalmic Ophthalmic Solution
Normalized name: hydroxypropyl methylcellulose ophthalmic ophthalmic solution
DrugBank: Propyl acetate (DB01670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03705637
Drug: Exparel
Normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Donor sites will receive up to 50mg of 0.25marcaine with epinephrine injected uniformly into the wound.~* The donor site will also receive one bottle (266mg) of Exparel, diluted to be administered uniformly into the entire donor site, spaced out ever 3-4cm. The dilution will be as follows:~  o 20ml Exparel + 10ml injectable 0.9% NS (30ml) for every 100cm2 of donor site.~* Injection of local anesthesia will be performed after the donor site has been harvested and is hemostatic. The goal is to provide the maximum time possible for the local anesthetic to work while under anesthesia, so it can benefit the patient and not be administered at the end of the case just prior to extubation.
Study: NCT04331795
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Group A: Tocilizumab (beginning dose 200mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.~Second dose is provisioned if:~1. Increasing supplemental oxygen requirement or Tmax higher than baseline in the 24h following initial tocilizumab administration AND~2. CRP decrease is \< 25% at 24 hours following tocilizumab administration and CRP \> 40mg/L
Study: NCT04331795
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Group B: Low-dose tocilizumab (beginning dose 80mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.~Second dose is provisioned if:~1. Increasing supplemental oxygen requirement or Tmax higher than baseline in the 24h following initial tocilizumab administration AND~2. CRP decrease is \< 25% at 24 hours following tocilizumab administration and CRP \> 40mg/L
Study: NCT02317861
Drug: Febuxostat
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Treatment
Study: NCT02317861
Drug: Benzbromarone
Normalized name: benzbromarone
DrugBank: Benzbromarone (DB12319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Treatment
Study: NCT01560780
Drug: Prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: one 10 mg tablet by mouth daily
Study: NCT00576459
Drug: 0.59 mg fluocinolone acetonide intravitreal implant
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.59 mg
Study: NCT00576459
Drug: 2.1 mg fluocinolone acetonide intravitreal implant
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.1 mg
Study: NCT03076203
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given orally
Study: NCT00761007
Drug: Ibodutant
Normalized name: Ibodutant
DrugBank: Ibodutant (DB12042)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet, dose level 1 (10 mg), once daily
Study: NCT00761007
Drug: Ibodutant
Normalized name: Ibodutant
DrugBank: Ibodutant (DB12042)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet, dose level 2 (30 mg), once daily
Study: NCT00761007
Drug: Ibodutant
Normalized name: Ibodutant
DrugBank: Ibodutant (DB12042)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet, dose level 3 (60 mg), once daily
Study: NCT03220542
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole
Study: NCT03220542
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin
Study: NCT01610570
Drug: Mithramycin
Normalized name: Mithramycin
DrugBank: Plicamycin (DB06810)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase I Portion: Mithramycin will be administered in escalating doses to children and adolescents intravenously over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression. If maximum tolerated dose (MTD) in this Phase differs from the recommended adult dose for Phase II, the protocol will be amended. Using a Simon two stage design, mithramycin will be administered intravenously at 17.5 microgram/kg over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression to children and adults with Ewing sarcoma with Ewings sarcoma - friend leukemia integration 1 transcription factor (EWS-FLI1) fusion transcript Both Phases will enroll patients simultaneously. Phase II Portion: mithramycin will be administered intravenously at 17.5 microgram/kg over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression to children and adults.
Study: NCT03279614
Drug: SOX
Normalized name: Vasoxyl
DrugBank: Methoxamine (DB00723)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OXA：130mg/m2 ，iv drip for 180min d1, S-1 40-60mg p.o. bid d1-14, q3W
Study: NCT02498015
Drug: 3D regimen with ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The 3D regimen with ribavirin contain paritaprevir/ritonavir/ombitasvir (75/50/12.5mg) once daily, dasabuvir 250mg twice daily, and ribavirin (1000 mg regardless of weight) daily in two divided doses for genotype 1a and genotype 1b with cirrhosis.
Study: NCT00721474
Drug: Bosutinib
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bosutinib fasting
Study: NCT00721474
Drug: Bosutinib
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bosutinib fed
Study: NCT03548935
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive semaglutide subcutaneous (s.c.; under the skin) injection(s) once-weekly as well as diet and physical activity counselling for 68 weeks. Dose escalation of semaglutide will take place as follows: 0.25 mg from week 1 to 4, 0.5 mg from week 5 to 8, 1.0 mg from week 9 to 12, 1.7 mg from week 13 to 16 and 2.4 mg from week 17 to week 68.
Study: NCT01432873
Drug: Oral selenium
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: selenium tablet Oral selenium 1 Tab bid from day -6/-7 until discharge
Study: NCT00502138
Drug: Continuous Pramlintide infusion
DrugBank: Pramlintide (DB01278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pramlintide injection, 9 mcg/hr plus 60 mcg premeal boluses
Study: NCT00315744
Drug: Salmeterol/fluticasone
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Salmeterol/ fluticasone are a type of long acting beta-agonist (LABA). Salmeterol 50 microgram/ fluticasone 100 microgram combination will be administered to eligible subjects via inhalation route.
Study: NCT00315744
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate is a type of LABA. Fluticasone 100 microgram dose will be administered to eligible subjects via inhalation route.
Study: NCT01527006
Drug: perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During the titration period, participants started at a set daily dose of 0.015 mg/kg and had doses up-titrated at 1-week intervals (6 titration steps) to a maximum daily dose of 0.18 mg/kg. During the Maintenance Period, participants continued taking perampanel oral suspension once daily at the dose level they achieved at the end of the Titration Period. During the extension phase, participants continued taking perampanel oral suspension once daily, at the dose level achieved at the end of the treatment phase of the core study to a maximum daily dose of 0.18 mg/kg. The maximum total daily dose a participant was allowed was 12 mg.
Study: NCT00501488
Drug: rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00315744
Drug: Salbutamol
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol metered dose inhaler will be provided to all subjects as a rescue medication.
Study: NCT01507337
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A single dose of 1 mg administered subcutaneously (under the skin)
Study: NCT00202787
Drug: FOLFOX-4+cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab; Weekly administration of Cetuximab IV (initial infusion of 400 mg/m2 for 120 minutes followed by subsequent maintenance doses of 250 mg/m2 for 60 minutes);~FOLFOX-4: Every two week Oxaliplatin; 85 mg/m2 ; day 1 Folinic acid; 200 mg/m2 ; day 1 and 2 5-FU ; Bolus 400 mg/m2 + CI 600 mg/m2 22 h day 1 and 2
Study: NCT01594515
Drug: BI 1015550
Normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose powder for oral solution
Study: NCT01594515
Drug: BI 1015550
Normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose powder for oral solution
Study: NCT01594515
Drug: BI 1015550
Normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose powder for oral solution
Study: NCT01594515
Drug: BI 101550
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose powder for oral solution
Study: NCT04472585
Drug: Ivermectin Injectable Solution
Normalized name: ivermectin Injectable Solution
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous Ivermectin 200ug/kg body weight 48 hourly
Study: NCT04472585
Drug: Oral Ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2mg/kg/day
Study: NCT02833012
Drug: Caprylic Triglyceride Oil
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g Caprylic Triglyceride Oil (10.5 mL) at Hour 0 on Day 1
Study: NCT02833012
Drug: AC-1204
Normalized name: ONL-1204
DrugBank: ONL-1204 (DB18239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g AC-1204 (shaken in 120 mL of water) at Hour 0 on Day 1
Study: NCT03755947
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib Oral Capsule \[Imbruvica\] Tablets 120 mg. Oral. 420mg/day, day 1 to 28, every 28 days. 3 cycles.
Study: NCT03755947
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab Injection. Intravenous Solution \[Gazyva\] Parenteral. 1000 mg, day 1 of every cycle, every 28 days. 6 cycles.
Study: NCT05679336
Drug: Rituximab, Cyclophosphamide, and Corticosteroids
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1. Rituximab (RTX) will be given as a single intravenous (IV) dose of 375 mg/m2. Extra RTX infusion at the same dose will be administered on weeks 12, 24, and 36 in the absence of remission and the occurrence of peripheral B-cell reconstitution. Peripheral B-cell reconstitution is defined as total CD19+ cell count \>5 cells/μL;~2. Concurrent with RTX initiation, a single IV infusion of methylprednisolone 500 mg will be administrated, followed by oral prednisolone 1 mg/kg daily but not exceeding 60 mg daily during week 1. The dosage will be rapidly decreased by 10 mg/weekly as follows: week 2, 50 mg daily; week 3, 40 mg daily; week 4, 30 mg daily; week 5, 20 mg daily; weeks 6-7, 10 mg daily; weeks 8-48, 5 mg daily; week 49, stop;~3. Four IV infusions of Cyclophosphamide will be administered at a dose of 7.5 mg/kg every other week (on weeks 1, 3, 5, and 7).
Study: NCT03755947
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax Oral Tablets \[Venclexta\] Tablets 100 mg. Oral. 400 mg/day. Day 1 to 28, every 28 days. 12 cycles.
Study: NCT00296062
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase I: irinotecan hydrochloride IV over 90 minutes on days 1 and 15 during course 1 and all subsequent odd-numbered courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.Phase II: receive capecitabine (at the MTD determined in phase I) in combination with irinotecan hydrochloride (during odd-numbered courses)
Study: NCT00296062
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase I: oxaliplatin IV over 2 hours on days 1 and 15 during course 2 and all subsequent even-numbered courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Phase II: oxaliplatin (during even-numbered courses) as in phase I
Study: NCT01299454
Drug: OPC-34712
Normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All groups will receive a single oral 2-mg OPC-34712 dose on Day 1 with 240 mL room temperature still water. Subjects will be administered the OPC-34712 dose in the fasted state (at least 8 hours of fasting) and no food will be allowed for 4 hours postdose. Water will be restricted as part of the dosing procedure from 1 hour prior to dosing and 2 hours post-dose.
Study: NCT03203616
Drug: KADCYLA 160 MG Injection
Normalized name: KADCYLA 160 MG Injection
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Kadcyla 160Mg Powder for Injection: 3.6 mg/kg iv every 3 weeks
Study: NCT01242267
Drug: Thalidomide+Melphalan +Bortezomib+stem cell transplant
Normalized name: Thalidomide
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Five days prior to transplant, the patient starts thalidomide. Dose range will be from 600mg for 5 days, to 1000mg for 5 days. Thalidomide dose is increased after groups of 3 to 6 patients have been treated. 4 days before the transplant and again on the day before the transplant the patient will be given bortezomib (VELCADE) intravenously at a dose of 1.6 mg/m2 (mg/m2 means that the dose will be calculated based on the patient's height and weight). 2 days before transplant the patient will be given melphalan 200 mg/m2 intravenously. Dexamethasone is given before the VELCADE and the melphalan.
Study: NCT01730508
Drug: Pegylated Interferon Alfa (Peginterferon Alfa)
Normalized name: Pegylated-interferon alfa 2a
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon alfa dosing and treatment duration are at the discretion of the investigator in accordance with China clinical practice and local labeling.
Study: NCT00585611
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin - 40 mg orally daily for 6 months
Study: NCT01518972
Drug: Prazosin
Normalized name: Prazosin
DrugBank: Prazosin (DB00457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Form: Prazosin will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg
Study: NCT01674166
Drug: prucalopride
Normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: single dose 0.03 mg/kg prucalopride open label
Study: NCT00919230
Drug: Ferrous sulphate tablets
Normalized name: Ferrous Fumarate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg twice daily for four weeks
Study: NCT03213964
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-2 (begin Day 0): 6 million units three times a week for a total of 6 doses. For patients weighing less than 45 kilograms, the IL-2 will be given at 3 million units/m2 three times a week for 6 doses.~The 1st dose will be given immediately (within 30 minutes) after the FATE-NK100 cell infusion on Day 0 as an inpatient. The remaining doses will be given in an outpatient setting.
Study: NCT03946891
Drug: Inhaled Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects in the A arm will receive 1 mg/kg of inhaled furosemide Q 24 hours for 3 days. This will be followed by a washout period of a day followed by 1 mg/kg of intravenous furosemide Q 24 hours for 3 days.
Study: NCT03946891
Drug: Intravenous Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects in the B arm will receive 1 mg/kg of intravenous furosemide Q 24 hours for 3 days followed by a washout period, which is then followed by 1 mg/kg of inhaled furosemide Q 24 hours for 3 days.
Study: NCT01713621
Drug: OZ439
Normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OZ439 is a novel synthetic trioxolane antimalarial agent
Study: NCT01786603
Drug: Rasagiline
Normalized name: Rasagiline
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rasagiline 2mg once a day for 12 months.
Study: NCT01499147
Drug: fludarabine/busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients below age 55, should receive fludarabine/busulfan, and ATG in case of unrelated or mismatched donor, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 \<40%, DLCO\<50%, LVEF\<40, Serum bilirubin \>1.5 mg% or serum transaminases \> 2x nl) and/or specific medical conditions such as preventing a standard myeloablative treatment, as per discussion with the PI.
Study: NCT01499147
Drug: fludarabine/ melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients above age 55 or below age 65, should receive fludarabine/melphalan, and ATG, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 \<40%, DLCO\<50%, LVEF\<40, Serum bilirubin \>1.5 mg% or serum transaminases \> 2x nl).
Study: NCT01499147
Drug: ATG
Normalized name: eATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving a transplant from a matched unrelated or mismatched related/unrelated donor would receive ATG in the conditioning regimen.
Study: NCT00321347
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04251910
Drug: Sublingual film containing Dexmedetomidine
Normalized name: dexmedetomidine Sublingual Film
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sublingual film containing Dexmedetomidine
Study: NCT00897377
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01610245
Drug: Nitazoxanide
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01610245
Drug: Oseltamivir
Normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02729714
Drug: Suvorexant
Normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg Suvorexant or matching Placebo orally at bedtime with optional up-titration to 15 mg Suvorexant or matching Placebo orally at bedtime after 2 weeks.
Study: NCT04577846
Drug: Cephalexin 500 MG
Normalized name: cephalexin 500 MG
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefalexin 500 mg PO q8 hours will be continued for the duration of the indwelling drains which usually is about 14 days.
Study: NCT03855579
Drug: Levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative infusion of Levosimendan
Study: NCT03855579
Drug: Milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative infusion of Milrinone